In particular, we show with high statistical significance that 177Lu-SN201 is superior at slowing the tumor growth and prolonging the life time compared to the commonly used cancer drugs paclitaxel, niraparib, carboplatin, and the combination of the immune check-point inhibitors anti PD-1 and anti-CTLA-4. Here, CTLA4 is linked to cancer.